肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Oncologist：CTC计数示转移性结直肠癌预后

2012-07-25 魏冬 医学论坛网

循环肿瘤细胞转移性结直肠癌预后
关注

《肿瘤医师》（Oncologist）杂志近期发表的一项研究表明，循环肿瘤细胞（CTC）计数是转移性结直肠癌患者无进展生存（PFS）和总生存（OS）预后的一个强预测因素。 　　结直肠癌维持治疗试验是一项Ⅲ期临床试验，目的是在转移性结直肠癌患者中评估贝伐珠单抗单药 对 贝伐珠单抗+化疗的效果。一项辅助研究评估了CTC计数作为疗效终点的预后和/或预测标志物的价值。 　　180例患

《肿瘤医师》（Oncologist）杂志近期发表的一项研究表明，循环肿瘤细胞（CTC）计数是转移性结直肠癌患者无进展生存（PFS）和总生存（OS）预后的一个强预测因素。

　　结直肠癌维持治疗试验是一项Ⅲ期临床试验，目的是在转移性结直肠癌患者中评估贝伐珠单抗单药 对 贝伐珠单抗+化疗的效果。一项辅助研究评估了CTC计数作为疗效终点的预后和/或预测标志物的价值。

　　180例患者入组。血样在基线和3个周期治疗后获取。CTC计数采用 CellSearch 系统检测。CT扫描被用于在第3和6个治疗周期时以及此后每12周评估肿瘤缓解情况。

　　结果显示，基线CTC计数≥3和＜3的患者中位PFS时间分别为7.8和12.0个月（P=0.0002），中位OS时间分别为17.0和25.1个月（P=0.0059）。

　　3个周期治疗后，CTC计数小的患者中位PFS时间为10.8个月，显著长于CTC计数大的患者的7.5个月（P=0.005）；CTC计数＜3患者的中位OS时间显著长于≥3的患者，分别为25.1和16.2个月（P=0.0095）。

原文链接：

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E.Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a spanish cooperative group for the treatment of digestive tumors study.Oncologist. 2012;17(7):947-55.

    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895548, encodeId=612c189554802, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 12 14:12:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864365, encodeId=fa521864365c2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 20 14:12:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386078, encodeId=ea1a13860e8b9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452596, encodeId=2fd114525962e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455095, encodeId=4c4b1455095b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-10-12 kalseyzl

    #CTC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1895548, encodeId=612c189554802, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 12 14:12:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864365, encodeId=fa521864365c2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 20 14:12:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386078, encodeId=ea1a13860e8b9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452596, encodeId=2fd114525962e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455095, encodeId=4c4b1455095b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2013-06-20 minlingfeng

    #Oncol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1895548, encodeId=612c189554802, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 12 14:12:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864365, encodeId=fa521864365c2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 20 14:12:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386078, encodeId=ea1a13860e8b9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452596, encodeId=2fd114525962e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455095, encodeId=4c4b1455095b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-07-27 1249842em09(暂无昵称)

    #转移性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1895548, encodeId=612c189554802, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 12 14:12:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864365, encodeId=fa521864365c2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 20 14:12:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386078, encodeId=ea1a13860e8b9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452596, encodeId=2fd114525962e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455095, encodeId=4c4b1455095b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-07-27 crystal0564

    #结直肠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1895548, encodeId=612c189554802, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 12 14:12:00 CST 2012, time=2012-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864365, encodeId=fa521864365c2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 20 14:12:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386078, encodeId=ea1a13860e8b9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452596, encodeId=2fd114525962e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455095, encodeId=4c4b1455095b3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-07-27 july_977

    #GIST#

    0

相关资讯

循环肿瘤细胞(CTC)用于乳腺癌治疗的证与辨

　　1869年，托马斯·阿什沃思（Thomas Ashworth）在1例转移性癌症患者血液中观察到了循环肿瘤细胞（CTC）——从实体瘤中脱离出来并进入血液循环的肿瘤细胞。他推测，这些细胞在癌症转移过程中发挥了非常重要的作用，并可能提供疾病进展的相关信息。 　　近年来，研究者围绕CTC在乳腺癌、结直肠癌、前列腺癌等多种实体瘤中的应用价值展开了深入探索。2004年发表于《新英格兰医学杂志》

早期乳腺癌患者查血或可预测复发和生存

根据《柳叶刀-肿瘤学》杂志6月6日在线发表的一项研究结果，对早期乳腺癌患者检测循环肿瘤细胞(CTC)或许能预测复发和生存的几率，并有助于确定哪些患者可能需要额外治疗(The Lancet Oncology. DOI: 10.1016/S1470-2045(12)70209-7)。   德克萨斯大学MD Anderson癌症中心的Anthony Lucci及其同事指出，基于既往研究结果